Skip to main content
Delfa

← All assets

EVP-6124

6 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

6

Ongoing

0

Recruiting

0

Completed

2

Sites

214

Countries

20

Endpoints

50

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 50 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
1
Phase 2
2
Phase 3
3

Trials by status

Completed
2
Terminated
3
Withdrawn
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Safety / tolerability / PK
24
Global cognition
11
Behavior / neuropsychiatric
4
Executive function / language
3
Function / daily living
3
Caregiver / quality of life
3
Other (unclassified)
2

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 15 of 50 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Mini-Mental State Examination (MMSE)Cognition

5

Neuropsychiatric Inventory (NPI)Behavior

4

ADAS-CogCognition

3

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

3

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

6 of 6

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT02004392Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025

EVP-6124

Alzheimer’s disease

Study partner/caregiver requiredPh 3Terminated86Aug 2017-
NCT01969123Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

EVP-6124

Alzheimer’s disease

Alzheimer's diseasePh 3Terminated82Jan 2017-
NCT01969136Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

EVP-6124

Alzheimer’s disease

Alzheimer's diseasePh 3Terminated81Jan 20171
NCT01073228Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease

EVP-6124

Alzheimer’s disease

Alzheimer's diseasePh 2Completed54Nov 2011-
NCT00766363Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease

Donepezil, EVP-6124, Rivastigmine

Alzheimer’s disease

Alzheimer's diseasePh 1Completed4Mar 2009-results
NCT02246075Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine

EVP-6124

Alzheimer’s disease

Alzheimer's diseasePh 2Withdrawn2Oct 2016-

Showing 1-6 of 6 trials